uniQure Announces Pricing of Upsized $225 Million Public Offering

uniQure N.V. announced the pricing of an underwritten public offering of 4,945,055 ordinary shares at $45.50 per share, generating approximately $225 million in gross proceeds. The offering is expected to close on June 25, 2026. The company is advancing gene therapies for hemophilia B, Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other severe conditions.